SRTS Sensus Healthcare, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1494891 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-53.3%
TTM net income YoY-433.4%
TTM EPS YoY-438.9%
Revenue 3-yr CAGR-12.7%
Net income 3-yr CAGR—
Margins
Gross margin41.8%
Operating margin-74.0%
Net margin-96.5%
FCF margin-69.4%
EBITDA margin-71.9%
Returns
ROE-37.0%
ROA-32.4%
ROIC (approx.)-39.5%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets12.6%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.00M | $2.29M | $3.39M | $4.94M | $6.88M | $7.32M | $8.34M | $13.07M |
| Cost of revenue | $2.71M | $1.52M | $2.40M | $3.04M | $4.17M | $4.41M | $3.99M | $5.96M |
| Gross profit | $3.29M | $769,000 | $991,000 | $1.90M | $2.71M | $2.90M | $4.35M | $7.11M |
| R&D expense | $1.11M | $1.11M | $1.59M | $1.88M | $1.82M | $1.47M | $2.61M | $1.56M |
| SG&A expense | $2.25M | $1.79M | $2.04M | $1.76M | $1.92M | $1.99M | $2.21M | $2.42M |
| Operating income | -$1.62M | -$3.18M | -$4.36M | -$3.15M | -$2.57M | -$1.94M | -$2.65M | $1.73M |
| Interest expense | — | — | — | — | — | -$183,000 | -$184,000 | — |
| Pretax income | -$1.49M | -$3.06M | -$4.23M | -$2.99M | -$2.41M | -$1.76M | -$2.46M | $1.96M |
| Income tax | $0 | $5.69M | -$1.61M | $174,000 | -$1.47M | -$723,000 | $110,000 | $410,000 |
| Net income | -$1.49M | -$8.75M | -$2.63M | -$3.17M | -$943,000 | -$1.04M | -$2.57M | $1.55M |
| EBITDA | -$1.54M | -$3.09M | -$4.26M | -$3.05M | -$2.47M | -$1.84M | -$2.56M | $1.81M |
| EPS (basic) | -0.09 | -0.53 | -0.16 | — | -0.06 | -0.06 | -0.16 | — |
| EPS (diluted) | -0.09 | -0.53 | -0.16 | — | -0.06 | -0.06 | -0.16 | — |
| Weighted avg. shares (diluted) | 16.46M | 16.46M | 16.46M | — | 16.32M | 16.32M | 16.34M | — |
| Banking | ||||||||
| Net interest income | $126,000 | $117,000 | $125,000 | $155,000 | $160,000 | $183,000 | $184,000 | $230,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $12.92M | $15.19M | $18.33M | $22.08M | $24.45M | $22.16M | $19.07M | $22.06M |
| Receivables | $1.40M | $1.68M | $3.58M | $6.04M | $9.34M | $12.62M | $18.02M | $19.73M |
| Inventory | $17.96M | $18.46M | $16.50M | $14.56M | $13.04M | $12.40M | $9.92M | $10.10M |
| Current assets | $34.58M | $37.68M | $42.59M | $45.89M | $50.20M | $52.22M | $54.20M | $56.74M |
| PP&E, net | $2.66M | $2.75M | $2.31M | $1.98M | $2.52M | $2.71M | $2.68M | $2.00M |
| Total assets | $40.55M | $41.26M | $51.55M | $53.04M | $58.30M | $58.85M | $60.21M | $62.16M |
| Current liabilities | $5.11M | $4.33M | $5.86M | $4.72M | $6.80M | $6.41M | $6.72M | $5.88M |
| Total liabilities | $5.11M | $4.40M | $6.00M | $4.94M | $7.10M | $6.79M | $7.18M | $6.34M |
| Shareholders' equity | $35.44M | $36.86M | $45.54M | $48.10M | $51.19M | $52.06M | $53.03M | $55.83M |
| Shares outstanding | 16.46M | 16.46M | 16.46M | 16.46M | 16.44M | 16.44M | 16.45M | 16.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.26M | -$3.13M | -$3.75M | -$2.21M | $2.29M | $3.12M | -$2.68M | -$827,000 |
| Capital expenditure | $5,000 | $8,000 | $3,000 | $158,000 | $4,000 | $27,000 | $7,000 | -$297,000 |
| Free cash flow | -$2.27M | -$3.14M | -$3.76M | -$2.37M | $2.29M | $3.09M | -$2.68M | -$530,000 |
| Investing cash flow | -$5,000 | -$8,000 | -$3,000 | -$158,000 | -$4,000 | -$27,000 | -$7,000 | $297,000 |
| Financing cash flow | — | — | — | -$5,000 | $0 | $0 | -$300,000 | $28,000 |
| Depreciation & amortization | $81,000 | $86,000 | $96,000 | $100,000 | $98,000 | $99,000 | $86,000 | $85,000 |
| Stock-based compensation | $70,000 | $70,000 | $70,000 | $76,000 | $0 | $5,000 | $79,000 | $122,000 |
| Share buybacks | — | — | — | $0 | $0 | $0 | $300,000 | — |
Free plan shows the latest 8 periods; Pro shows all 46 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.